“Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort

Table 4 Comparison of predictive accuracy for overall survival between “Six-and-Twelve” score and staging/scoring systems (multicenter French cohort n = 324)

Scoring/stage systems	1-yr AUROC	P (vs ref)	2-yr AUROC	P (vs ref)	3-yr AUROC	P (vs ref)	C-index	P (vs ref)
“6&12” score	0.65 [0.57-0.74]	Ref	0.65 [0.59-0.71]	Ref	0.64 [0.58-0.71]	Ref	0.66 [0.58-0.74]
BCLC staging	0.61 [0.54-0.67]	0.1827	0.64 [0.59-0.70]	0.7079	0.61 [0.55-0.68]	0.2317	0.61 [0.54-0.68]	NS
NIACE score	0.75 [0.68-0.83]	0.0134	0.69 [0.64-0.75]	0.2368	0.69 [0.63-0.74]	0.2827	0.70 [0.64-0.77]	NS
Child-Pugh class	0.56 [0.49-0.63]	0.1057	0.56 [0.51-0.60]	0.0217	0.55 [0.50-0.59]	0.0304	0.59 [0.55-0.64]	NS
ALBI grade	0.63 [0.57-0.69]	0.6835	0.56 [0.51-0.61]	0.0479	0.55 [0.49-0.61]	0.1033	0.62 [0.55-0.68]	NS

“6&12”: “Six-and-twelve”; AUROC: Area under receiver operating characteristic curve; C-index: Concordance index; Ref: Reference; BCLC: Barcelona Clinic Liver Cancer; NS: Not significant; NIACE: Tumor nodularity, infiltrative nature of the tumor, alpha-fetoprotein, child-pugh class, performance status; ALBI: Albumin-Bilirubin.